Cellular Immunotherapy With Autologous T Lymphocytes Stimulated With the Patient's Tumor-Specific Mutated Ras Peptides
OBJECTIVES: I. Determine the feasibility of expansion and the reinfusion of specific T-cell
lines (peptide-specific activated lymphocytes), in combination with interleukin-2, in
patients who were vaccinated with ras peptides. II. Assess immunologic status or antitumor
response that may occur with this treatment in these patients.
OUTLINE: Autologous peptide-specific activated lymphocytes (PAL), previously harvested from
the patient following vaccination on a different protocol, are expanded and reinfused
intravenously; this is followed by a 4 hour observation period. Patients then receive
interleukin-2 (IL-2) administered subcutaneously 5 days a week for 2 weeks; the first dose
of IL-2 is administered at least 4 hours after PAL infusion. Patients are followed once a
month for 2 months after treatment.
PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study.
Primary Purpose: Treatment
Samir N. Khleif, MD
National Cancer Institute (NCI)
United States: Federal Government
|Medicine Branch||Bethesda, Maryland 20892|